ReviewAnalytical science advances2025
Cost-Effective Nanosensor Solutions for Ultra-Sensitive Detection of Metronidazole.
Review in Analytical science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dual-Functional PC/PL/N-CQD Hydrogel for Brilliant Green Degradation and Metronidazole Detection.Journal of fluorescence · 2026Article
- Mechanistic pseudo-two-dimensional modeling of redox-mediated electrochemical reduction of metronidazole at cobalt oxide nanostructured electrodes.RSC advances · 2026Article
- Emerging Biosensor Technologies for Stroke Biomarker Detection: A Comprehensive Overview.Analytical science advances · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metronidazole (MNZ) is a widely used imidazole antibiotic effective against bacterial and protozoal infections, including giardiasis, trichomoniasis, bacterial vaginosis, and antibiotic-associated colitis. However, prolonged and excessive use of MNZ can lead to serious side effects, such as peripheral neuropathies, toxicity, and optic neuropathy. Therefore, the accurate detection and removal of MNZ present significant technical challenges. This manuscript introduces novel approaches for the development and integration of precise and cost-effective sensors specifically designed for the accurate measurement of MNZ levels. We explore cutting-edge nanotechnology strategies for detecting MNZ, with a particular focus on innovative nanobiosensors, including photodynamic-based biosensors, acousto dynamic sensors, and electrochemical biosensors. Additionally, we delve into the unique challenges and opportunities associated with multiphysics biometric biosensors and related nanotechnologies in the detection of MNZ. This review not only provides insights and scientific evidence regarding the application of nanobiosensors for the accurate measurement of MNZ but also highlights recent advancements in sensor technology that represent a significant leap forward in this field. By emphasizing these novel contributions, we aim to pave the way for future research and development in this critical area. Ultimately, our findings underscore the importance of reliable detection methods in mitigating the risks associated with MNZ use and improving patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.